Adalimumab retreatment successfully restores clinical response and health‐related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 4, 2015-04 ,pp. : 767-776

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 31, Iss. 12, 2017-12 ,pp. : e518-e519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti‐infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 346-355

John Wiley & Sons Inc

Access to resources Recommend Favorite

Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : 400-405

John Wiley & Sons Inc

Access to resources Recommend Favorite

Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : e166-e166

John Wiley & Sons Inc

Access to resources Recommend Favorite